<div data-page-id="doxcnPs1GbxSMekJAtAFv2yx81d" data-docx-has-block-data="true"> <div class="image-uploaded gallery old-record-id-doxcnKGEcAsIEQsA6grxyI7Xogf" data-type="image" data-ace-gallery-json="{&quot;items&quot;:[{&quot;uuid&quot;:&quot;5181c6ef-0424-4ba5-a7e0-7a026a48b590&quot;,&quot;height&quot;:501,&quot;width&quot;:1000,&quot;currHeight&quot;:501,&quot;currWidth&quot;:1000,&quot;natrualHeight&quot;:501,&quot;natrualWidth&quot;:1000,&quot;pluginName&quot;:&quot;imageUpload&quot;,&quot;scale&quot;:1,&quot;src&quot;:&quot;https%3A%2F%2Finternal-api-drive-stream.feishu.cn%2Fspace%2Fapi%2Fbox%2Fstream%2Fdownload%2Fall%2FboxcneuFtvvMsHT6F3mKxR5Hpch%2F%3Fmount_node_token%3DdoxcnKGEcAsIEQsA6grxyI7Xogf%26mount_point%3Ddocx_image&quot;,&quot;file_token&quot;:&quot;boxcneuFtvvMsHT6F3mKxR5Hpch&quot;,&quot;image_type&quot;:&quot;image/png&quot;,&quot;size&quot;:957657,&quot;comments&quot;:[]}]}"><img style="display: block; margin-left: auto; margin-right: auto;" src="https://info.compassedu.hk/sucai/content/1659948794766/1659948794766.png" width="808" height="405" /></div> <div class="ace-line ace-line old-record-id-doxcnsEqcSeK6iumAQNTmgHAiIg" style="text-align: justify;"><span class="p">&nbsp;</span></div> <div class="ace-line ace-line old-record-id-doxcn6ssYsmscGsKy0621qP5qye" style="text-align: justify;"><span class="h6">圖片：上圖顯示了兩種形式的分枝桿菌菌落形成。分枝桿菌F-ATP合酶（左）是新化合物的靶標(biāo)，該化合物被證明對(duì)殺死細(xì)菌有效（右）。</span></div> <div class="ace-line ace-line old-record-id-doxcn6ssYsmscGsKy0621qP5qye" style="text-align: justify;">&nbsp;</div> <div class="ace-line ace-line old-record-id-doxcn60Mwesu2O2kCY8V1UEEoQf" style="text-align: justify;"><span class="p"><em> </em></span></div> <div class="ace-line ace-line old-record-id-doxcnQcak6GCm02aWYHkINhRrQb" style="text-align: justify;"><span class="p">一系列可以殺死耐多藥結(jié)核?。═B）的新型化合物，由<strong>新加坡南洋理工大學(xué)</strong>和<strong>實(shí)驗(yàn)藥物開發(fā)中心（EDDC）</strong>的聯(lián)合團(tuán)隊(duì)開發(fā)和商業(yè)化，該中心是由<strong>科學(xué)，技術(shù)和研究局（A * STAR）</strong>主辦的國(guó)家藥物發(fā)現(xiàn)和開發(fā)平臺(tái)。</span></div> <div class="ace-line ace-line old-record-id-doxcncQK4IweKGayGGUteQklT6f" style="text-align: justify;"><span class="p">&nbsp;</span></div> <div class="ace-line ace-line old-record-id-doxcnQKaWoo0uYY6sIL6PfFAFae" style="text-align: justify;"><span class="p">美國(guó)<strong>Neuro-Horizon Pharma</strong>公司對(duì)這些化合物進(jìn)行許可，該公司將使用這些化合物來(lái)制造可以對(duì)抗結(jié)核病的新藥，結(jié)核病對(duì)現(xiàn)有藥物治療的耐藥性越來(lái)越大。</span></div> <div class="ace-line ace-line old-record-id-doxcn8sWeMYCkIwMau07fvuBSPf" style="text-align: justify;"><span class="p">&nbsp;</span></div> <div class="ace-line ace-line old-record-id-doxcnWeAgkeygsaaIqaAJVhzhhe" style="text-align: justify;"><span class="p">根據(jù)世界衛(wèi)生組織的數(shù)據(jù)，結(jié)核病是僅次于COVID-19的第二大傳染病殺手，估計(jì)每年有150萬(wàn)人死于結(jié)核病。發(fā)展中國(guó)家和發(fā)達(dá)國(guó)家都出現(xiàn)了更多的結(jié)核病疫情。例如，新加坡衛(wèi)生部宣布，6月初，在武吉美拉路的一個(gè)大型聚集性病例中，有170人經(jīng)檢測(cè)呈結(jié)核病陽(yáng)性。</span></div> <div class="ace-line ace-line old-record-id-doxcnM8CUMusuGocOs9UcVZ28hh" style="text-align: justify;"><span class="p">&nbsp;</span></div> <div class="ace-line ace-line old-record-id-doxcn6Sq2yQk2SW0SK0XPY0odwd" style="text-align: justify;"><span class="p">新化合物的研究和開發(fā)由NTU和EDDC與美國(guó)發(fā)現(xiàn)與創(chuàng)新中心Hackensack Meridian Health（CDI）合作完成，并得到<strong>新加坡國(guó)家研究基金會(huì)的支持</strong>。</span></div> </div>